@ibdseb

IBD clinician& researcher @IBDHull. Governing Board :ECCO own views, RT🚫endorse.⚽️@LFC fan.

 England
scholar.google.com/citations?user=hF98UvsAAAAJ&hl=enhttps://orcid.org/0000-0002-3670-6545
Joined August 2010
  • Tweets9.3K
  • Following1.2K
  • Followers3.8K
1.1KMedia
Great feedback about this session particularly from those who were not able to go to 🇺🇸 this year - thank you . Cross organisational collaborative sessions are needed given the pace of read outs of trials Thank you also for putting MINIMISE on the list 😊
Aline Charabaty, MD, FACG, AGAF@DCharabatyOct 20
A true privilege to represent the @AmerGastroAssn w AGA President @BCryer & review Best of #IBD of #DDW26 at @my_ueg ✅FUZION ✅DUET-CD ✅ARTEMIS-UC ✅COMPARE-IBD ✅MIMIMISE ✅Summary 👇🏽 Congrats @joostphdrenth @schattenbergJ for a fabulous #UEGWeek w 🌟research & faculty🌟
1
1
3
742
Thank you @TakuKobayashiM1 Missed this one this am - This is now published in full ?
Taku Kobayashi@TakuKobayashiM1Oct 20
ANTHEM-UC Phase 2b study presented by Britta Siegmund! Icotrokinra, a first-in-class targeted oral IL-23 receptor peptide, demonstrated remarkable histologic and endoscopic efficacy in UC through Week 28. A huge step forward for oral targeted therapies! #IBD #UEGWeek @MyueGodo
1
3
460
ANTHEM-UC Phase 2b study presented by Britta Siegmund! Icotrokinra, a first-in-class targeted oral IL-23 receptor peptide, demonstrated remarkable histologic and endoscopic efficacy in UC through Week 28. A huge step forward for oral targeted therapies! #IBD #UEGWeek @MyueGodo
9
1
20
1,424
A true privilege to represent the @AmerGastroAssn w AGA President @BCryer & review Best of #IBD of #DDW26 at @my_ueg ✅FUZION ✅DUET-CD ✅ARTEMIS-UC ✅COMPARE-IBD ✅MIMIMISE ✅Summary 👇🏽 Congrats @joostphdrenth @schattenbergJ for a fabulous #UEGWeek w 🌟research & faculty🌟
1
10
2
52
3,100
Duvakitug in UC Phase 2 LTE #Reinish #UEGWeek2026
4
12
1,038
Another first in class agent based on P selectin glycoprotein ligand Phase 2a No Placebo All patients exposed to biologics and/or small molecules . 🤔Can we predict who needs this approach Presented by @IBDMD
3
9
717
Phase 2 of novel class molecule with PDE4B selective inhibitor MUFEMILAST Oral agent Presented by @PeyrinBiroulet at #UEGWeek2026 Need to see phase 3
8
10
690
Replying to @ibdseb @PeyrinBiroulet @vipuljairath @alisontalbot72 @IbdHull
Arguably, the most important IBD study in recent times. Congratulations to the team
1
5
440
Time to reflect and celebrate #VERDICT With those who were instrumental in conceiving (@PeyrinBiroulet ) and delivering (@vipuljairath ) Fitting tribute to #ProfFeagan Thanks to all the patients who participated in this practice changing study
2
5
1
47
2,894
New tricks using existing drugs adds value in care #AFFIRM
Aline Charabaty, MD, FACG, AGAF@DCharabatyOct 19
Excited to be part of #AFFIRM presented #UEGWeek @my_ueg #RISA SC induction 🔺At wk12 , in AT naïve/ AT-exposed 🩺Clinical Remissn 73/45% 🔦Endo improvmt 61/34% 🔦Endo remission 45/18%
3
1
9
752
STRIDE 3 presented and published in @LancetGastroHep Congratulations to all @DignassAxel Pragmatic and time dependent 👏 Full paper thelancet.com/journals/langa…
9
1
29
1,271
Combination therapy ABBV-466 (RIZA+TROSU) seems to have added benefit in endoscopic healing at Wk12 and 24 with no additional infection risk Presentation from @RPanaccione with some of exploratory mechanistic insights #uegweek2026
9
16
1,143
#VERDICT @my_ueg Results 👇 without comment and for discussion
Seb@ibdsebOct 19
The most anticipated study in #IBD over last few years #VERDICT being presented at #UEGW2026 @my_ueg Barcelona in 5 minutes @vipuljairath @alimentiv @IbdHull @TakedaPharmaUK
4
13
2,026
Seb retweeted
Seb@ibdsebOct 19
The most anticipated study in #IBD over last few years #VERDICT being presented at #UEGW2026 @my_ueg Barcelona in 5 minutes @vipuljairath @alimentiv @IbdHull @TakedaPharmaUK
1
2
10
4,600
The most anticipated study in #IBD over last few years #VERDICT being presented at #UEGW2026 @my_ueg Barcelona in 5 minutes @vipuljairath @alimentiv @IbdHull @TakedaPharmaUK
1
2
10
4,600
Congratulations
Mythili Menon Pathiyil(she/her)@menon_mythiliOct 16
Grateful and honored to receive the auxiliary award at #ACG2026. Thank you to @pelegnoam @UpstateNews for the guidance and support, and @AmCollegeGastro for this recognition. Next step : IBD fellowship! 🚀🤞🏻
2
498
If you are coming ti @my_ueg congress in Barcelona, do not miss this tomorrow!!
1
9
21
1,939
Fascinating study in @AGA_Gastro Microbial food metabolism is disrupted by intestinal inflammation, causing food sensitization via colonic mast cell responses, possibly explaining common adverse food reactions reported by IBD patients
Harry Sokol@h_sokolOct 16
1/7 85-86% of IBD patients in remission report food intolerances, versus 33% of controls. A Gastroenterology paper argues inflammation causes this: colitis depletes the bacteria that digest dairy proteins, and colonic mast cells do the rest. gastrojournal.org/article/S0…

Gut Inflammation Favors Adverse Food Reactions by Disrupting the Microbial Metabolism of Food...

Intestinal inflammation facilitates sensitization to gluten and dairy by depleting microbes that digest them, potentially contributing to the increase in adverse food reactions among inflammatory...

gastrojournal.org
6
25
1,571
Great work @pedsIBDdoc Indeed the disparities in access to s/c infliximab is astonishing
Elizabeth A Spencer MD MS@pedsIBDdocOct 17
Kids with IBD can switch from IV to subcutaneous infliximab and stay well. My meta-analysis of 173 children (6 studies) in Current Gastroenterology Reports: 93% stayed in remission, 92% stayed on drug. The barrier in the US is age-based denials, not the drug. #IBD #PedsIBD link.springer.com/article/10…
3
8
503
Replying to @Bealoquebea @fgomollon @DCharabaty @JosephHabibi_MD @ibdseb @IBDimmunology @ShomronH @drvishal82 @ign76 @sepdigestiva @aegastro
Great resource! For #PedsIBD colleagues, the NASPGHAN TDM position paper (Felipez et al, JPGN 2025) addresses children’s faster clearance: higher starting doses, BSA-based dosing <40 kg, and earlier levels in high-risk kids. pmc.ncbi.nlm.nih.gov/article…

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on...

Inflammatory bowel diseases (IBD) require effective therapies to prevent morbidity and maintain quality of life. The introduction of biologic agents, beginning with monoclonal antibodies targeting...

pmc.ncbi.nlm.nih.gov
6
9
468
Load more